Revel Pharmaceuticals Strengthens Board of Directors and Scientific Advisory Board

Jennifer Cochran and Vincent Monnier

Revel Pharmaceuticals, a privately held biotechnology company creating therapeutics to reverse and repair damage that results from aging, today announced recent additions to its Board of Directors and Scientific Advisory Board.

Joining as a member of the Board of Directors is Jennifer Cochran, Ph.D. “We are thrilled to attract stellar leadership that matches the level of promise of Revel’s mission of attacking diseases of aging,” said Aaron Cravens, Revel co-founder and CEO. “Augmenting our Board leadership with Dr. Cochran’s insights and experience will ensure that Revel Pharmaceuticals has the guidance to maximize the therapeutic promise of our technology.”

Dr. Cochran joins the Revel Pharmaceuticals Board of Directors with over 25 years of experience in the discovery and development of therapeutics. Dr. Cochran has co-founded several biotechnology companies including xCella Biosciences which develops antibody therapeutics, and is a Venture Partner at Lagunita Biosciences. Since 2008, she has served as a Professor of Bioengineering at Stanford University, and is presently Shriram Chair of Bioengineering at Stanford University. She also serves as the Director of the Stanford/NIH Biotechnology predoctoral training program. Her expertise spans protein-based drug discovery and development for applications in regenerative medicine, oncology and ophthalmology, and development of new technologies for high-throughput protein analysis and engineering. Dr. Cochran obtained her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, where she also completed a postdoctoral fellowship in Biological Engineering. She has received numerous accolades for her work including the National Cancer Institute Howard Temin Award, and an American Cancer Society Research Scholar Award. Dr. Cochran has published over 75 papers in peer-reviewed journals and is named as an inventor on over 35 patent applications. “I am delighted to join Revel’s Board and work with the team to build a transformative new class of therapeutics around AGE-breaking enzymes” stated Jennifer Cochran.

Joining as a member of the Scientific Advisory Board is Vincent Monnier, Ph.D. “Revel will benefit massively from Dr. Monnier’s decades of expertise and study of the molecular mechanisms of aging” said Patrick Burgermeister, Board Member and Partner at Kizoo.

Dr. Monnier joins Revel’s Scientific Advisory Board with over 45 years of experience working in clinical pathology and study of the Maillard reaction, Advanced Glycation End Products (AGEs) and how they relate to aging and complications of diabetes. Dr. Monnier is a Professor of Pathology at Case Western Reserve University with a research focus on elucidation of the molecular mechanisms by which the aging process leads to impairment of protein function. Dr. Monnier discovered that the AGE glucosepane is the single most significant cross-link in senescent human tissues. “AGE-breaking enzymes are a novel and promising therapeutic and I am thrilled to join the team at Revel Pharmaceuticals, the leader in developing an enzyme-based therapy targeting glucosepane and other AGEs, which drive diverse diseases of aging” said Dr. Monnier.


Revel Pharmaceuticals is a biotechnology company located in San Francisco, CA. with a technology platform based on the work of Yale Professors David Spiegel and Jason Crawford. We are commercializing therapeutic designer enzymes to degrade molecular damage that accumulates with aging. By addressing one of the hallmarks of aging, Revel is strategically positioned to develop therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes

About Kizoo

KIZOO provides mentoring and seed and early-stage financing with a focus on rejuvenation biotechnology. Having been entrepreneurs, VCs, and mentors in both high-growth tech and biotech companies for many years, with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech – a young industry that will eventually become much bigger than today’s largest technology markets.

As part of the Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include AgeX, FoxBio,, Elevian, Oisin Biotechnologies, Underdog Pharmaceuticals, MAIA Biotechnology, REVEL Pharmaceuticals, and others.

Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidence-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference.